Home Preston Registration Register for Preston Speaker: Dr David Eaton Venue: The Macdonald Tickled Trout - Preston New Road, Preston, PR5 0UJ A live stream from London will connect all delegates, bringing engaging and interactive discussions straight to you across the country, followed by immersive sessions on key topics of interest at regional venues. View Agenda AGENDA × TIME SESSION SPEAKER(S) 18:00-19:00 Arrivals and dinner 19:00-19:10 Where are we now in the management of HER2+ metastatic breast cancer? Dr John Conibear 19:10-19:40 Optimising second line treatment for HER2+ metastatic breast cancer Dr Melissa Phillips, Maria Lapuente 19:40-20:10 MDT discussion: Practical management of patients on Enhertu Chaired by Dr John Conibear; Presented by: Maria Lapuente; Dr Melissa Phillips; Dr Mukesh Mukesh 20:10-20:30 Panel Q&A All Speakers 20:30-21:00 Regional focus sessions NB: Please note the agenda can be subject to change REGISTER HERE Title *First Name * required *Last Name * required *Job Title * required WORK ADDRESS *Organisation / Hospital Name * required *Town * required *Postcode * required CONTACT INFORMATION *Email * required Additional Email (CC Address) Telephone Number Dietary Requirements *I wish to register my place at this meeting and accept the information on Data Privacy. As a result of my registration, I understand I might receive promotional emails about this event, including joining instructions or reminder emails. Yes I confirm * required I hereby consent to receive email(s) from Daiichi Sankyo and AstraZeneca. These emails may contain non-promotional and/or promotional content. Yes No By opting in to Daiichi Sankyo and AstraZeneca's mailing list you will receive both promotional and/or non-promotional emails from both companies, including invitations to webinars and meetings. Please note that each company must verify your contact details against its own Healthcare Professional contact information database and if your contact details are already available within the AstraZeneca database a representative from AstraZeneca will email you to confirm your opt-in status. Alternately, if your details are already available within Daiichi Sankyo database a representative from Daiichi Sankyo will send you an email. In the scenario of your contact details not being available within either company's respective database, a Daiichi Sankyo and/or AstraZeneca representative will contact you to advise how you can be added to the database and confirm your opt-in status. If you have elected to receive information about any of Daiichi Sankyo or AstraZeneca's productions or services and wish to opt-out of receiving such information you can do so by sending an email to the respective company. For AstraZeneca email privacyrequests@astrazeneca.com and for Daiichi Sankyo email data-protection@daiichi-sankyo.eu. There is also an unsubscribe link at the bottom of our mailings that can be clicked if you wish to opt-out. Please note that registration does not automatically guarantee a place at this meeting. An email confirmation will be sent upon successful registration. Please only enter your email here if you are not a real person. PhonePlease enter your phone number here if you are a robot. When you're ready to send the form, uncheck this box and continue. This helps keep our forms secure. Please uncheck this box to continue Submit Your email address and personal information will be used to communicate electronically with you about this meeting. If you do not wish to receive any communication, then please email us at her2registration@HCPMED.NET. Thank you for registering× Thank you for registering to attend the HER2 Horizons: Connecting the dots in breast cancer care meeting on Thursday, 3rd July 2025. An email confirming your registration will be sent to the email address you provided. Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App store. Adverse events should also be reported to Daiichi Sankyo UK Pharmacovigilance on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk. UK/ADC/04/25/0011 | May 2025